About this trial
The inflammatory storm in critically ill patients releases cytokines, causing systemic immune damage, which may be an important cause of multiple organ failure and even death. Inflammatory storms exacerbate the deterioration of the disease in those children. Gamma globulin may be an effective option to control inflammatory storms. However, this preliminary result needs to be verified from reliable and representative RCTs. In our study, we conducted a retrospective study on the use of gamma globulin and an unused control group. At present, the indications of IVIG are mainly focused on the neuromuscular system and the blood system. We hope to establish a more appropriate and operable evaluation table for the suitability of gamma globulin for clinical use.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
children hospitalized in PICU of Children's Hospital of Fudan University
Children With Severe Infection Complicated With Inflammatory Storm
Disqualifiers
discharge within 48 hours
patients without informed consent
incomplete clinical and demographic data
Trial population
All children hospitalized in PICU of Children's Hospital of Fudan University from January 2022 to December 2023
Trial design
Cohort
Retrospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
The death rate of children
The death rate of children in 28 days after their discharged from PICU
length of stay in PICU
Time from PICU admission to discharge
Secondary outcomes
CD4+/CD8+
levels of peripheral blood subgroup of T lymphocyte (digital form)
C-reactive protein (CRP)
C-reactive protein (digital form)
IL-2R
The interleukin-2 receptor (digital form)
TNF-alpha
Tumor necrosis factor alpha (digital form)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.